Search
Now showing items 21-25 of 25
Cost‑effectiveness of add‑on dapagliflozin for heart failure with reduced ejection fraction patients without diabetes
(
Taylor & Francis
, 2024 , Article)
Aim: To evaluate the cost-effectiveness of dapagliflozin added to standard of care (SoC) versus SoC in heart failure with reduced ejection fraction (HFrEF) and without type 2 diabetes mellitus (T2DM) patients from the ...
Societal health and economic burden of cardiovascular diseases in the population with type 2 diabetes in Qatar. A 10-year forecasting model
(
Wiley-Blackwell
, 2023 , Article)
Aims: To predict the future health and economic burden of cardiovascular disease (CVD) in type 2 diabetes (T2D) in Qatar. Materials and Methods: A dynamic multistate model was designed to simulate the progression of fatal ...
Efficacy and safety of selinexor for patients with relapsed and refractory multiple myeloma: A meta-analysis
(
Elsevier
, 2024 , Article)
PurposeSelinexor is a first-in-class, oral selective-inhibitor-of-nuclear-export, granted accelerated approval by FDA (2019) for relapsed and refractory multiple myeloma (RRMM). We sought to quantitatively summarize the ...
The cost associated with the development of the antimicrobial stewardship program in the adult general medicine setting in Qatar
(
Taylor and Francis Ltd.
, 2024 , Article)
Objective: To estimate the economic impact of the developed antimicrobial stewardship program (ASP) versus the preliminary ASP use, in the adults' general medicine settings in Qatar. Methods: Patient records were retrospectively ...
Cost-effectiveness Analysis of Ibuprofen versus Indomethacin or Paracetamol for the Treatment of Patent Ductus Arteriosus in Preterm Neonates.
(
Elsevier
, 2023 , Article)
This was a first-time evaluation that sought to analyze the cost-effectiveness of oral paracetamol and intravenous (IV) indomethacin as alternatives to ibuprofen for PDA in neonates. Decision-analytic, literature-based, ...